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Key Points
• Therapy with an IL-15
superagonist resulted
in immune and clinical
responses in a transplant
recipient with PML.
Introduction
Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease of the central nervous
system caused by reactivation of the John Cunningham virus (JCV). JCV is common; however, most
infected patients will remain asymptomatic.1 In the setting of immunosuppression, including after
allogeneic hematopoietic cell transplant (HCT), the virus is transformed and may infect oligoden-
drocytes, causing a course of progressive neurologic decline. PML is generally rapidly fatal. There is no
effective antiviral treatment of JCV or PML, but immune reconstitution is essential. In the post-HCT
setting, the risk of developing PML does not appear to have an end point, and time to development of
symptoms can range from weeks to decades.
Interleukin-15 (IL-15) is critical for the proliferation and activation of natural killer (NK) cells and CD81
memory T cells. N-803, a novel IL-15 superagonist, contains a mutant form of IL-15 (N72D), in complex
with the soluble domain of the IL-15 receptor (IL-15Ra), resulting in a prolonged serum half-life and
increased biologic activity compared with wild-type IL-15.2 Here, we report a case of PML following
allogeneic HCT in which neurological improvement occurred following treatment with N-803.
Case description
A 27-year-old HIV-negative male with no significant medical history was diagnosed with T-cell acute
lymphoblastic leukemia in January 2016. The patient was treated according to Cancer and Leukemia
Group B 10403. Cerebrospinal fluid (CSF) cytology was negative at diagnosis and remained negative
throughout therapy. Following a 10/10 matched-unrelated donor allogeneic HCT in May 2016, the
patient achieved minimal residual disease negativity with complete donor engraftment. All immunosup-
pression was tapered off by February 2017. CD4 count at this time was 458. The patient was free of any
neurologic deficits and was able to return to work full time.
On 14 July 2017, 460 days posttransplant, the patient presented with left shoulder pain, left arm
heaviness, and asymmetric left shoulder fullness but no weakness or neurologic deficits. There was no
history of injuries or trauma. Cervical spine magnetic resonance imaging (MRI) was unremarkable, and
CSF analysis showed no evidence of leukemia. Ten days later, he developed new weakness in the left
lower and upper extremities, with loss of fine motor skills in the left hand and diminished deep tendon
reflexes in the left upper and lower extremities but no numbness or sensory deficits. A short course of
prednisone (2 mg/kg 3 7 days) was administered, with no improvement.
Over the next week, the patient’s weakness progressed to paralysis, and he was no longer able to
ambulate, requiring a wheelchair. Brain MRI showed a posterior right frontal subcortical white matter
lesion, hyperintense on T2/fluid-attenuated inversion recovery (FLAIR) without enhancement or diffuse
restriction, concerning for PML. A repeat lumbar puncture was performed, and qualitative polymerase
chain reaction (PCR) was positive for JCV, confirming the diagnosis. Mefloquine (250 mg daily3 3 days,
then 250 mg weekly) and mirtazapine 30 mg daily were initiated on 7 August 2017. Due to lack of
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improvement and progression of weakness after 14 days, N-803, an
IL-15 superagonist, (6 mg/kg subcutaneously on days 1, 8, 15, and
22 of a 28-day cycle) was added under compassionate use (single-
patient IND #136501) from the US Food and Drug Administration
on 21 August 2017.
Methods
Flow cytometry
Cryopreserved peripheral blood mononuclear cells (PBMCs) were
analyzed by flow cytometry as previously described.3
VP1-specific CD81 T cells (peptides VP169-ESDSPNRDMLPCY,
VP1183-NTEHKAYLDKNKAY, and VP1329-GTEELPGDPDMMRY
from New England Peptide, Gardner, MA) were loaded into HLA-
A*01 monomers by UV-mediated exchange and multimers were
generated using streptavidin-conjugated phycoerythrin or allophy-
cocyanin (Invitrogen, Carlsbad, CA).4 PBMCs were cultured with
peptides for 12 days (primary stimulation) or 19 days (secondary
stimulation with peptides on day 12), dual stained with tetramers,
and analyzed by flow cytometry.
Results and discussion
Repeat brain MRI after 2 N-803 cycles on 16 October 2017
showed a worsening extent of the FLAIR abnormality (Figure 1).
However, the patient’s strength was improving, and treatment was
continued. Subsequent brain MRIs demonstrated marked improve-
ment in the T2/FLAIR white matter lesions, and the most recent
brain MRI, 759 days after initiation of N-803, continued to
demonstrate response. Qualitative CSF JCV PCR has remained
undetected since December 2017. CSF specimens were sent to
the National Institutes of Health (NIH) for ultrasensitive quantitative
JCV PCR, and the DNA copy number decreased from 31 copies/mL in
December 2017 to 16 copies/mL in February 2018 and 11 copies/mL
in April 2018. Identification of the JCV DNA variant as prototype
was performed at the NIH using the Multiplex qPCR assay. N-803
was stopped after 8 total cycles, and the patient continues to take
mefloquine and mirtazapine. His neurologic deficits continue to
improve, and he is now able to ambulate with a cane. His last
follow-up examination was April 2020 (1926 days after initiation of
N-803 therapy), and he remains stable with slow and steady neurologic
improvement and no evidence of graft-versus-host disease or acute
myeloid leukemia.
While the absolute number of circulating T and B cells decreased
during N-803 treatment, we observed a more than threefold
increase in the number of circulating CD56bright and CD56dim NK
cells (Figure 2A). Phenotyping of peripheral blood T cell subsets
revealed little to no changes within the CD31CD41 T cell subsets
(Figure 2B-F). In contrast, there was a decrease in the relative
percentage of naive CD31CD81 T cells with a concomitant
increase in effector memory and effector memory RA cells during
N-803 treatment. This shift in the CD31CD81 T cell population
toward an effector phenotype was accompanied by an increase in
the number of CXCR3-expressing cells as well as evidence of cell
activation as determined by increased expression of CD38, HLA-DR,
perforin, granzyme B, and the proliferation marker Ki-67 (Figure
2B-F). These findings are consistent with previously reported data.5,6
Using the Immune Epitope Database major histocompatibility com-
plex class I peptide-binding prediction algorithm, we found 3 puta-
tive antigens from the JCV major capsid protein VP1 with predicted
binding (50% inhibitory concentration ,500 nM) to the patient’s
HLA-A*01:01 allele. We stimulated PBMCs obtained before and
after N-803 treatment with the VP1-derived peptides and stained
cultures with peptide-specific HLA-A*01:01 tetramers. No JCV
VP1 peptide-specific CD81 T cells were detected (data not
shown).
This report further suggests that N-803 may enhance the clearance
and resolution of a viral illness in humans. A preclinical study in
monkeys showed that N-803 leads to suppressed replication of an
HIV-like virus.7 Preliminary data in HIV-positive patients demon-
strated increased numbers of CD41 and CD81 T cells, increased
NK cells, and increased HIV transcription following N-803.8 In the
post-HCT setting, N-803 administration significantly increased NK
and CD81 T cells numbers and function. This phenotype was
associated with temporary cytomegalovirus clearance9 and may
enhance the clearance of relapsed/refractory acute myeloid leuke-
mia, without increasing rates of immunosuppression-requiring graft-
versus-host disease.5 Thus, N-803 may augment antitumor and
antiviral immunity in humans.
Novel therapeutic approaches for PML have included immunother-
apy, and case reports supporting the use of IL-2,10-13 IL-7,14-20
vaccination,20,21 PD-1 inhibitors,22-26 and adoptive T cell therapy27,28
have been published. Lymphopenia is the main risk factor for PML,
and the lesions typically lack a lymphocytic infiltrate. Upon immune
A B C D
Figure 1. FLAIR MRI images. Axial FLAIR MRI images were obtained before initiation of N-803 (A), after 2 cycles (B) and 8 cycles (C) of N-803, and 759 days after initiation
of N-803 (D), demonstrating improvement in the posterior right frontal subcortical white matter lesion.
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restoration, CD81 T-cell–predominant lymphocytic infiltrates de-
velop, often corresponding with transiently worsening symptoms, MRI
findings, or both.29 This process, called immune reconstitution
inflammatory syndrome, 30 is perhaps consistent with our patient’s
observed MRI findings after 2 cycles of N-803. Brain biopsy/autopsy
samples from HIV-positive and HIV-negative patients with PML
demonstrated that recruitment of CD81 T cells is associated with
control of JCV infection.31,32 Although HLA-A*02:01-restricted
epitopes derived from the JCV VP1-protein have been characterized
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Days after initiation of ALT-803
F
Figure 2. Impact of N-803 on peripheral
blood cell subsets. Cryopreserved PBMCs
were assessed by flow cytometry immediately
before (day 0) and at the indicated timepoints
after initiation of N-803 treatment. (A) The
absolute numbers of cells per microliter of
peripheral blood for each subset was determined
by multiplying the percentage of a given cell type
(relative to the total CD451 population) by the
overall white blood cell count. Fold changes in
each subset are relative to the baseline (day 0)
sample. (B) Relative percentages of naive, central
memory (CM), effector memory (EM), and
CD45RA-expressing effector memory (EMRA)
CD31CD41 or CD31CD81 T cell subsets. (C)
Relative percentages of CD31CD41 or CD31
CD81 T-cell subsets expressing the chemokine
receptors CD183 (CXCR3), CD194 (CCR4),
and/or CD196 (CCR6). The Th1, Th2, and Th17
designated in parentheses are only applicable to
the CD31CD41 T cell subset. (D) The percent-
age of CD31CD41 or CD31CD81 T cells
expressing cell-surface antigens that are altered
during T cell activation. (E) The percentage of
CD31CD41 or CD31CD81 T cells expressing
molecules involved in immune checkpoint regula-
tion. (F) The percentage of CD31CD41 or
CD31CD81 T cells expressing intracellular per-
forin (Pfn), granzyme B (GzmB) or the pro-
liferation marker KI67.
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to 3 putative peptide epitopes predicted to bind HLA-A*01:01 with
high affinity. Our failure to detect JC-specific CD81 T cells to these
3 peptides suggests that the VP1-derived epitopes determined
bioinformatically were either not antigenic or the frequency of
responding VP1-specific CD81 T cells in the peripheral blood
was less than the limit of detection (0.1%) of the tetramer-based
flow cytometry assay. We acknowledge that our peptide screen
for JCV-specific T cells in this patient was very limited and that
the JC virus–specific T cells may have been enriched in the CSF
rather than the peripheral blood. Although several immunogenic
JCV-derived peptides recognized by both CD41 and CD81 T cells
from PML patients have been reported, none have been restricted
to our patient’s HLA-A01*01 allele.27,33-37 Therefore, additional
functional studies are needed to determine if N-803 promotes anti-
JC virus immunity via NK cells, CD81 and CD41 T lymphocytes, or
some sort of their combination.
In summary, N-803 represents a possible therapeutic option for
treatment of PML in post-allogeneic HCT patients, and further
prospective studies are warranted.
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